Tulmimetostat

3 trials 3 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

3 Recruiting

0 Completed trials

1 Sponsors

7 Countries

Phase I/II

Phase I (FiH)

Phase I/II: 2 Phase I (FiH): 1

Sponsors using this IMP

Novartis Pharma AG 3

All trials

3 total

A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting

2025-521880-10-00 Phase I/II 6 countries Novartis Pharma AG
TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat… Recruiting

2025-521873-15-00 Phase I/II 5 countries Novartis Pharma AG
DZR123 (CPI-0209) in Patients with Advanced Solid Tumors and Lymphomas Recruiting

2023-508002-20-00 Phase I (FiH) 4 countries Novartis Pharma AG

Showing 1–3 of 3 trials

← All drugs A–Z